Covshield production to rise to 12 crore per month, Covaxin to 5.8 crore: Minister of Health

Monthly production of Covishield and Covaxin is expected to increase to over 12 crore and 5.8 crore, respectively, Union Health Minister Mandaviya told Rajya Sabha on Tuesday.

Responding to a question on current vaccine production, the minister said production capacity is expected to increase from August to December, according to information from manufacturers.

“As communicated by the manufacturers, Covishield’s monthly vaccine production capacity is expected to increase from 110 million doses per month to more than 120 million doses per month and the production capacity of Covaxin is expected to increase from 25 million doses per month . at around 58 million doses per month, ”he said in a written response.

The minister said that the biotechnology department, under the Ministry of Science and Technology, had launched the “Covid Suraksha Mission – India’s mission to develop the Covid-19 vaccine”.

As part of the assignment, increasing the facilities of Bharat Biotech, a state-owned public sector enterprise and two central public sector (ESP) enterprises – Haffkine Biopharmaceutical Corporation Ltd, Mumbai; Indian Immunologicals Limited (IIL), Hyderabad and Bharat Immunologicals Biologicals Limited (BIBCOL), Bulandshahr – for the production of Covaxin were supported.

In addition, the technology transfer of the production of Covaxin to the Gujarat Covid Vaccine Consortium (GCVC), including Hester Biosciences and OmniBRx Biotechnologies Pvt Ltd, led by the Gujarat Biotechnology Research Center (GBRC) of the Department of Science and Technology of the Government of Gujarat, has also been made easier. , says the answer.

The Center also provided financial assistance to one of the domestic manufacturers for ‘risk-making’, advance payment on supply orders placed with Serum Institute of India and Bharat Biotech, in addition to streamlining regulatory standards for the vaccine approval, the response added.

Mandaviya also said that four other Indian pharmaceutical companies are expected to start production of coronavirus vaccines by October-November, which will speed up the inoculation campaign.

He said India has administered 47 crore doses so far and the Center is working to vaccinate the whole country as soon as possible.

Even 7-9% of doses not used by private hospitals are used by government vaccination centers, he added.

“The vaccination campaign is going smoothly … It will accelerate further in the coming days with the increased production of four other Indian companies,” said the minister.

According to Mandaviya, Biologicals E and Novartis vaccines will also be available on the market in the coming days, while Zydus Cadila will soon get an emergency opinion from an expert committee.

Currently, two companies – Bharat Biotech and Serum Institute – are supplying the vaccine to the government. The Sputnik vaccine is also available and production has started, he added.

To a question from BJD member Amar Patnaik about the vaccine rollout plan for 12-18 year olds and the need for a third or fourth dose, Mandaviya said, “The government’s goal is to vaccinate all of the population. the population as soon as possible and constant efforts. are made to achieve it. “

To subscribe to Mint newsletters

* Enter a valid email address

* Thank you for subscribing to our newsletter.

Never miss a story! Stay connected and informed with Mint. Download our app now !!

Source link

About Tiffany Wright

Check Also

Study finds 95% of renewable energy capacity in wealthier countries

© Gnanamclicks With the release of the long-awaited IPCC report, the race to decarbonise is …

Leave a Reply

Your email address will not be published. Required fields are marked *